"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Rescula (unoprostone isopropyl) Ophthalmic Solution 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) twice daily.
Rescula may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If two drugs are used, they should be administered at least five (5) minutes apart [see PATIENT INFORMATION].
Dosage Forms And Strengths
Unoprostone isopropyl ophthalmic solution 1.5 mg/mL.
Storage And Handling
Rescula (unoprostone isopropyl) Ophthalmic Solution 0.15% is supplied sterile in a low-density polyethylene bottle with a low-density polyethylene dropper tip, a turquoise polypropylene closure, and a clear tamper-evident shrinkband.
5 mL in a 7.5 mL bottle NDC 17350-015-05
Store between 2° - 25°C (36° - 77°F).
Marketed by: Sucampo Pharma Americas, LLC, Bethesda, MD 20814This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/3/2013
Additional Rescula Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.